Susceptibility of Mycobacterium tuberculosis Cytochrome bd Oxidase Mutants to Compounds Targeting the Terminal Respiratory Oxidase, Cytochrome c-Reference-Cited by-同舟云学术

Susceptibility of Mycobacterium tuberculosis Cytochrome bd Oxidase Mutants to Compounds Targeting the Terminal Respiratory Oxidase, Cytochrome c

Published:2017-10 Issue:10 Volume:61 Page:
ISSN:0066-4804
Container-title:Antimicrobial Agents and Chemotherapy
language:en
Short-container-title:Antimicrob Agents Chemother

Author:

Moosa Atica¹,Lamprecht Dirk A.²,Arora Kriti³,Barry Clifton E.³⁴,Boshoff Helena I. M.³,Ioerger Thomas R.⁵,Steyn Adrie J. C.²⁶⁷,Mizrahi Valerie¹⁴,Warner Digby F.¹⁴^ORCID

Affiliation:

1. MRC/NHLS/UCT Molecular Mycobacteriology Research Unit, DST/NRF Centre of Excellence for Biomedical Tuberculosis Research, Department of Pathology, University of Cape Town, Cape Town, South Africa

2. Africa Health Research Institute, Durban, South Africa

3. Tuberculosis Research Section, Laboratory of Clinical Infectious Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland, USA

4. Institute of Infectious Disease & Molecular Medicine, University of Cape Town, Cape Town, South Africa

5. Department of Computer Science and Engineering, Texas A&M University, College Station, Texas, USA

6. Department of Microbiology, University of Alabama at Birmingham, Birmingham, Alabama, USA

7. Centres for AIDS Research and Free Radical Biology, University of Alabama at Birmingham, Birmingham, Alabama, USA

Abstract

ABSTRACT We deleted subunits I ( cydA ) and II ( cydB ) of the Mycobacterium tuberculosis cytochrome bd menaquinol oxidase. The resulting Δ cydA and Δ cydAB mutants were hypersusceptible to compounds targeting the mycobacterial bc 1 menaquinol-cytochrome c oxidoreductase and exhibited bioenergetic profiles indistinguishable from strains deficient in the ABC-type transporter, CydDC, predicted to be essential for cytochrome bd assembly. These results confirm CydAB and CydDC as potential targets for drugs aimed at inhibiting a terminal respiratory oxidase implicated in pathogenesis.

Funder

HHS | National Institutes of Health

Foundation for the National Institutes of Health

National Research Foundation

South African Medical Research Council

Publisher

American Society for Microbiology

Subject

Infectious Diseases,Pharmacology (medical),Pharmacology

Link

https://journals.asm.org/doi/pdf/10.1128/AAC.01338-17

Reference19 articles.